Fulcrum Therapeutics, Inc. business relationships
Companies named in Fulcrum Therapeutics, Inc.’s 10-K filed 2026-02-24, and public companies whose annual reports name Fulcrum Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.0 / 10
- AI naming
- 27 / 100 Top 2% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Fulcrum Therapeutics, Inc.’s annual report 6
“...hich, if any, of the components of the losmapimod agreement are performance obligations with a customer and concluded that the losmapimod license and the Sanofi territory-specific manufacturing activities are within the scope of ASC 606 because Sanofi is the Company's customer in those transactions.” SEC filing
“Additionally, the Company was entitled to sales milestones and royalties from Sanofi upon future sales of losmapimod in the Sanofi territory, and revenue would have been recognized when the related sales occur.” SEC filing
“Accordingly, we will not recognize additional revenues under the Sanofi collaboration agreement.” SEC filing
“The Company determined that the Sanofi Agreement contained three material promises: (i) the license granted to Sanofi to develop and commercialize losmapimod outside of the United States (the "losmapimod license"); (ii) the parties' joint global development activities for losmapimod; and (iii) the S...” SEC filing
“the progress and results of our exclusive global license agreement with CAMP4 Therapeutics Corp., or CAMP4;” SEC filing
“collaborations may be terminated for the convenience of the collaborator (e.g., our former collaborations with Acceleron Pharma, Inc. and MyoKardia, Inc., the latter of which was terminated on June 26, 2025), and, if terminated, we could be required to raise additional capital to pursue further deve...” SEC filing
Companies whose annual reports name Fulcrum Therapeutics, Inc. 1
“The proprietary intellectual property licensed pursuant to this agreement is related to certain legacy programs we are not pursuing, which were subsequently sublicensed to Fulcrum Therapeutics, Inc. ("Fulcrum"), as described below.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.